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There is evidence that proinﬂammation may be linked to the development of hypertension (HT). We examined the association
of both the interleukin-1 beta (IL-1β) and the interleukin 1-receptor antagonist (IL-1ra) with future blood pressure (BP) and HT
occurrence (BP ≥ 140/90mmHg, or antihypertensive drug) in a population-based prospective study. Our study consisted of 396
(147 men and 249 women) middle-aged, baseline apparently healthy, normotensive subjects participating in a 6.5-year follow-up
study. Subjects with high-sensitivity CRP (hs-CRP) < 10mg/L were excluded at the initial visit. At follow-up, the occurrence of
HTwas 32%.Thelevels ofbaseline IL-1β andIL-1rawere signiﬁcantlyhigher forsubjectswhodeveloped HTduringthefollow-up
than for those who did not (IL-1β;0 . 6 7± 0.62 pg/mL versus 0.56 ± 0.32 pg/mL, P = .020 and IL-1ra; 184 ± 132pg/mL versus
154 ± 89pg/mL, P = .007). After adjustments for age, follow-up time, sex, baseline systolic BP, and BMI, our results conﬁrm a
statistically signiﬁcant (P = .036) linear association between the quartiles of IL-1β and change of systolic BP during the study.
After adjustments for age, follow-up time, sex, and BMI, our results also show a linear association between incident HT and the
quartiles of IL-1ra. (P = .026). These results provide evidence that proinﬂammation may precede BP elevation and HT.
Copyright © 2008 Mauno Vanhala et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
There exists a growing body of evidence describing the
role of cytokines in the context of hypertension (HT)
[1–5]. Interleukin-1beta (IL-1β) is a crucial mediator of
inﬂammatory response. Animal experiments that examined
the vascular wall of hypertensive rats showed an increase in
mRNA expression levels of IL-6, IL-1β,a n dT N F - a l p h a[ 6].
Previous human work has shown increased levels of IL-1β in
the systemic circulation of patients with essential HT. Most
IL-1β is secreted by peripheral blood monocytes instead of
adipocytes in hypertensive subjects, and angiotensin II (Ang
II) may be directly involved in the process of monocyte
activation [7]. IL-1β and Ang II together may also regulate
sympathetic nervous system (SNS) activity through negative
feedback by modulating the expression of nitric oxide
(NO) in the brain [8–10]. IL-1β could also be an addi-
tional risk factor for atherogenesis in hypertensive patients
[11].
The production and eﬀects of IL-1β are controlled at
many levels, a critical one being the inhibition of its activities
by the secreted form of the interleukin-1 receptor antagonist
(IL-1ra) [12]. Elevated concentrations of this substance have
been connected to insulin resistance and type 2 diabetes
[13] .M o r e o v e r ,e l e v a t e dl e v e l so fI L - 1 r ah a v eb e e nf o u n di n
subjects with essential HT [14]. Even if proinﬂammation is
linkedtocardiovasculardisease(CVD),therecurrentlyexists
no evidence showing that IL-1ra could have an independent
role in the etiology of CVD [15].
IL-1β also stimulates the synthesis of hs-CRP and other
inﬂammatory mediators [16–18]. It has been speculated that
inﬂammation plays an important role in triggering vascular
ﬁbrosis, which is an important aspect of extracellular matrix
remodeling in hypertension [19]. Another research has
proven that CRP predicts future cardiovascular events, at
least in women [20].
Baseline blood pressure (BP), obesity, use of alcohol, and
lack of physical activity have traditionally been suggested
as precursors of HT that works via mechanisms including
proinﬂammation and insulin resistance [21, 22].
Despite several reliable cross-sectional studies show-
ing the connection of IL-1β and IL-1ra to hypertension,2 Mediators of Inﬂammation
researchers have not yet conclusively linked these proin-
ﬂammatory markers to blood pressure in a longitudinal
study. Accordingly, we examined the two aforementioned
proinﬂammatory markers, lifestyle factors, and other tra-
ditional risk factors in a normotensive, apparently healthy
population. Our goal was to understand their roles in both
future BP changes and HT in follow-up examinations.
2. MATERIALS AND METHODS
2.1. Subjects
A l ls u b j e c t s( N = 1294) were born in 1942, 1947, 1952,
1957, and 1962 in Pieks¨ am¨ aki, a town in eastern Finland.
The patients were invited to participate in a general health
examinationin1997-1998.Atotalof923ofthe1294subjects
(71.3%) participated in an initial examination in 1997-1998,
and 690 of those underwent a second checkup in 2003-2004.
The mean follow-up time was 6.45 (range 5.3–7.4) years.
There were no additional examinations between these two
checkups. All participants gave informed written consent.
Thestudy protocolwasapproved by theEthics Committee of
theKuopioUniversityHospitalandtheUniversityofKuopio.
All participants completed a standard questionnaire in
the beginning and at the end of the study. It included
questions about smoking habits, use of alcohol, and physical
activity. Those who smoked daily were classiﬁed as smokers.
Use of alcohol was measured using a scale with ten graded
levels: 0 = never used, 1 = not used alcohol in the last year,
3 = used less than 1 unit (standard drinks)/week, 4 = 1-2
units/week, 5 = 3–5 units/week, 6 = 6–9 units/week, 7 = 10–
14 units/week, 8 = 15–21 units/week, 9 = 22–28 units/week,
and 10 = more than 29 units/week. A subject was classiﬁed
as drinking more than the recommended 1-2 doses/day if
he/she consumed 10 or more alcohol units/week. Physical
activitywasmeasuredusingascalethatcomprisedsixgraded
levels. The patients were asked to deﬁne physical exercise
as suﬃciently strenuous exertion that results in perspiration
and breathlessness. 1 = daily exercise, 2 = three or more
times/week, 3 = twice/week, 4 = about once/week, 5 =
once/month, and 6 = less than once/month. A subject was
classiﬁedasphysicallyactiveifhe/sheexercisedthreeormore
times per week.
All patients with hs-CRP > 10mg/L at the initial exam-
ination were excluded due to the fact that they might have
had an active infection. Since certain cardiovascular drugs
can aﬀect BP and cytokines, all patients taking medication
for another cardiovascular disease were excluded in the
beginning of the study.
2.2. Clinicalandlaboratorymethods
Height and weight were measured to the nearest 0.5cm and
0.1kg, respectively. Body mass index (BMI) was calculated
as weight (kg) divided by height (m) squared. The waist
was measured to the nearest 1.0cm at the midpoint between
the lateral iliac crest and the lowest rib. Trained nurses
measured BP twice with subjects in a seated position
using a mercury sphygmomanometer. The mean of two
measurements was used for subsequent statistical analyses.
Measurements were performed at the initial and ﬁnal visits.
Hypertension was determined to be present if subjects had a
BP ≥140/90mmHg or if subjects were taking antihyperten-
sive medication [23].
Fasting blood samples were drawn after 12 hours of
fasting. C-reactive protein (CRP) was measured with an
Immulite (R) and a DPC high-sensitivity CRP assay (hs-
CRP). Plasma concentrations of IL-β and IL-1ra were
measured using assay kits from R&D Systems (Minneapolis,
Minn, USA; for IL-1β, resolution power was 0.125–8pg/mL
and sensitivity 0.1pg/mL; for IL-1ra, resolution power was
46.9–3000pg/mL and sensitivity 22pg/mL). Cytokines were
measured during the initial examination.
2.3. Statisticalanalysis
The results were expressed as means, standard deviations
(SDs), ranges, and 95 percent conﬁdence intervals (95%
CI). IL-1β and IL-1ra exhibited skewed distributions and
were, therefore, logarithmically transformed for statistical
analysis. The t-test and chi-squared test were used to derive
statistical comparisons between genders or between groups
of hypertensive and normotensive subjects in respect of
baseline characteristics and other subgroup parameters. The
hypotheses of linearity between quartiles of plasma cytokine
levels and changes in systolic BP or occurrence of HT
were analyzed with two general linear models known as the
analysisofcovariance(ANCOVA)andwithlogisticalmodels.
All models were adjusted for gender, age, baseline BMI,
follow-up time, and baseline systolic BP when appropriate.
All statistical tests were two sided, withan alpha-level of 0.05.
3. RESULTS
Of the 233 nonparticipant subjects, 48% (n = 112) were
men and 52% (n = 121) were women. Our data shows
no statistical diﬀerence in BP, BMI, age, or lifestyle factors
in nonparticipants as compared with the participants. Of
the 690 participants, 406 subjects (59%) had a BP <
140/90mmHg and were not undergoing antihypertensive
drug treatment at the time of the baseline checkup. Six of
these patients had hs-CRP > 10mg/L, and four subjects
were taking a certain drug for another CVD; all of such
participants were excluded. Thus, the ﬁnal study population
consisted of 396 apparently healthy subjects (147 men and
249 women).
At the initial checkup, mean systolic BP was 126 ±
8mmHg in male patients and 122 ± 10mmHg in female
subjects (P between sexes < .001). Mean diastolic BP was,
respectively, 77 ± 6mmHg and 75 ± 7mmHg (P<. 001).
B M Ii nm e nw a sh i g h e rt h a ni nw o m e n( 2 5 .9 ± 3.1kg/m 2
versus 25.1 ± 3.6kg/m 2, P between sexes = .029). Twelve
percent of men consumed 10 or more units of alcohol each
week, and this was statistically signiﬁcantly higher than the
2% of women who reported the same alcohol consumption
(P between sexes < .001). There was no sex-related diﬀerence
in physical activity. The percentages of physically active
subjects were 30% in men and 28% in women.Mauno Vanhala et al. 3
The levels of cytokines recorded at the baseline checkup
were statistically similar for both sexes. The level of IL-1β
was 0.59pg/mL ± 0.43pg/mL in men and 0.58pg/mL ±
0.43pg/mL in women. The corresponding ﬁgures for IL-
1ra were 157pg/mL ± 92pg/mL in men and 168pg/mL ±
102pg/mL in women. There was no statistically signiﬁcant
correlation between these two cytokines.
Betweentheinitialandfollow-upexaminations,smoking
decreased from 28% to 23% in men and from 21% to 17% in
women, and consumption of 10 or more alcohol units/week
increased from 12% to 18% in men and from 2% to 4% in
women. The percentage of physically active subjects did not
change.
Between examinations, the systolic BP increased 9 ±
12mmHg and the diastolic BP increased 4 ± 8mmHg. In
total, 128 (32.3%) of the 396 subjects, 59 men (41%) and
69 women (27%, P = .005 between sexes), developed HT.
Five of those 59 men and 14 of those 69 women were
prescribed antihypertensive medication between the initial
and the subsequent visit.
At the end of the follow-up, six (4%) men and seven
(3%) women were receiving drug treatment for another
cardiovascularcondition.Theuseofantilipolyticmedication
increased among the men from four (3%) to 28 (19%) users,
and in women from two (1%) to 27 (11%) users over the
duration of our study. In those subjects treated with lipid-
lowering drugs at the end of the study, the mean systolic BP
by the end of our study was 138 ± 16mmHg, as compared
to 131 ± 14mmHg in the nontreated subjects (P<. 001
between groups). The corresponding ﬁgures for diastolic BP
were 82 ± 9mmHg and 80 ± 9mmHg, P = .060.
Table 1 shows that the mean level of baseline IL-1β was
signiﬁcantlyhigheramongthosesubjectswhohaddeveloped
hypertension between the initial and the subsequent visits as
compared to those subjects who were normotensive at the
time of the second checkup (0.56pg/mL versus 0.67pg/mL,
P = .020). The same phenomenon was present in the levels
of IL-1ra (154pg/mL versus 184pg/mL, P = .007).
The systolic BP increased 6 ± 14mmHg from the
lowest to the highest quartile of IL-1β. This diﬀerence was
statistically signiﬁcant (P = .008). The BP values sorted
by quartile of IL-1β concentration were 129 ± 13mmHg,
132 ± 16mmHg, 130 ± 14mmHg, and 135 ± 15mmHg
(P for linearity = .019). Figure 1 shows that after adjusting
gender, age, follow-up time, BMI, and baseline systolic BP,
a statistically signiﬁcant (P = .036) linear association was
evidenced between the quartiles of IL-1β and the change in
the systolic BP during the follow-up. Further adjustment for
smoking, use of alcohol, and physical exercise at baseline did
not change the results. Taking into account lipid-lowering
medication or drugs for other cardiovascular disease did not
change these results.
The prevalence rates of incident HT, from the lowest
to the highest quartile of IL-1ra , were as follows: 26.5%,
23.2%, 34%, and 45.5% (crude P = .003 for linearity). The
increase in HT occurrence from the lowest to the highest
quartile of IL-1ra was 19% (P = .05 after adjustments for
gender, age, baseline BMI, and follow-up time). Table 2 and
Figure 2showthattherewasalsoalinearassociationbetween
HT incidence and quartiles of IL-1ra (P = .026) after
adjustments as previously described. Further adjustment for
smoking, use of alcohol, and physical exercise at baseline did
not change the results. Taking into account lipid-lowering
medication or drugs for other cardiovascular disease did not
change these results.
4. DISCUSSION
To the best of our knowledge, this study is the ﬁrst
prospective, population-based study providing evidence that
highlevelsofproinﬂammatorycytokineIL-1βprecedefuture
changes in systolic BP and in levels of its speciﬁc antagonist
IL-1ra in the context of HT. These associations were present
after adjustments for sex, age, BMI, and follow-up time;
they also remained for analyses that only examined BP from
baseline.
Earlier ﬁndings suggest that the pressor eﬀect of IL-1β is
mediated by AT1 receptors and depends on the stimulation
and the release of Angiotensin II (Ang II). [20, 21]A n gI I
raises BP via its peripheral and central eﬀects. In the brain,
ANG II downregulates neuronal NOS (nNOS) and leads
to the decrease of NO production and the increase of SNS
activity [8, 9, 18, 24]. There are also observations that IL-
1β downregulates SNS activity by increased local expression
of NOS mRNA as well as that Ang II-mediated increases in
arterial BP can be caused by inhibition of the expression of
IL-1β and nNOS at the brain level [10]. ANG II and IL-1β
may thus act in a negative feedback loop in the central BP
control system [8]. It seems possible that central IL-1β is also
involved in stress-induced HT [25].
The unbalanced production of IL-1β, and of its nat-
ural speciﬁc inhibitor IL-1ra , plays an important role in
chronic/sterile inﬂammation [12]. IL-1ra is an acute phase
reactant for IL-1β, since it reﬂects inﬂammatory reactions,
acts in an antagonistic manner, and serves as a natural com-
pensatory mechanism for the IL-1-induced disease process.
IL-1ra concentrationsincreaseduring both insulin resistance
and the metabolic syndrome [13]. A human experiment has
shown that IL-1β induces the secretion of IL-1ra , and that
induction of IL-1β precedes secretion of IL-1ra.
In our study, IL-1β is independently associated (even
after taking into account age, sex, baseline BMI, and certain
lifestyle factors) with changes in systolic BP that may reﬂect
an incipient change in arterial stiﬀness. High levels of IL-1ra
seem to be linked to occurrence of HT, and this can most
likely be explained by the fact that those subjects already in
the initial examination exhibited elevated BP subsequently
developed stable HT (deﬁned as ≥140/90mmHg and/or
prescribed antihypertensive drugs). These ﬁndings are in
line with previous data suggesting that proinﬂammation
precedes HT and that it may be a trigger for arterial wall
stiﬀness [20].
Lipid-lowering medications and some drugs used to
treat cardiovascular diseases other than HT may have BP
lowering eﬀects [26]. Evidence also suggests that lipid-
lowering medications can aﬀect the levels of cytokines [27].
Therefore, we excluded subjects who were using this kind
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Figure 1: Change of systolic blood pressure (mmHg) by IL-1β and IL-1ra quartiles among 377 baseline normotensive subjects without
antihypertensive drug treatment at the end of the 6.5-year prospective study. Adjusted for gender, age, baseline BMI, baseline systolic blood
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Figure 2: Occurrence of hypertension (RR ≥ 140/90mmHg or drug treatment for hypertension) over a 6.5-year timeframe according to
quartiles of baseline IL-1β and IL-1ra . Adjusted for gender, age, baseline BMI, and follow-up time.Mauno Vanhala et al. 5
Table 1: Baseline characteristics of 396 baseline normotensive subjects according to hypertension status at the end of the follow-up period.
HT−: normotensive at the end of study, HT+: hypertensive at the end of study (blood pressure ≥140/90mmHg and/or antihypertensive
drug use), and CVD: cardiovascular disease.
HT− HT+ P
n = 268 n = 128
Number of female = 249/396 (63%) 180 (67%) 69 (54%) —
Age (years) 50.6 ±6.1 53.0 ± 51 <.001
Follow-up time (years) 6.4 ±0.46 .4 ±0.4 .091
BMI (kg/m2)2 5 .1 ±3.62 6 .0 ±3.61 1
IL-1β (pg/mL) 0.56 ±0.32 0.67 ±0.62 .020
IL-1ra (pg/mL) 154 ± 89 184 ± 132 7
Lipid-lowering drug at the beginning of the study 1% 3% .091
Lipid-lowering drug at the end of the study 9% 26% <.001
Drug for some other CVD at the end of the study 3% 6% .398
Smoking 30% 26% .807
Alcohol > 10 units/week% 5% 6% .807
Physically active 25% 33% .086
Table 2: Odds ratios of hypertension (≥140/≥ 90mmHg or drug treatment for hypertension) according to quartiles of plasma levels of
baseline IL-1β and IL-1ra.
Variable Quartile of plasma level P for linearity∗
I II III IV
IL-1β
Median (range), pg/mL 0.25 (0.088–0.378) 0.48 (0.379–0.566) 0.63 (0.567–0.696) 0.82 (0.700–5.540)
Odds ratio (95% CI) 1.00 1.47 (0.79 to 2.73) 0.83 (0.43 to 1.58) 1.55 (0.84 to 2.89) .46
IL-1ra
Median (range), pg/mL 84 (46–98) 117 (99–139) 163 (140–192) 244 (193–1134)
Odds ratio (95% CI) 1.00 0.61 (0.31 to 1.20) 1.07 (0.56 to 2.04) 1.82 (0.95 to 3.46) .026
∗P-values were calculated by using a logistic model, adjusted for gender, age, follow-up time, and baseline body mass index.
has shown that lifestyle factors like exercise, smoking, and
consumption of alcohol can aﬀect both BP and HT [21, 22].
Therefore, we used the baseline information to correct our
analyses for these potential confounding factors.
During the course of the study, 59 men (41%) and 69
women (27%, P = .005 between sexes) developed HT.
This is consistent with both earlier results [22] and the
knowledge that middle-aged men are at greater risk for
all cardiovascular diseases than women. Our study also
showed that lipid-lowering medications were prescribed
more frequently for men; this ﬁnding is also consistent with
the present recommendations [26]. Antilipolytic medication
use increased during the study, especially among those
subjects who developed HT. Therefore, the increase occurred
in subjects with a high risk for having HT and dyslipidemia
simultaneously.
One strength of this study lies in its population-based,
prospective design, which includes both men and women
and evaluates many traditional risk factors simultaneously.
We also took into account the possibility that lifestyle factors
and some drug treatments may have an eﬀect on the results
by correcting our analysis for these confounding factors.
Lifestyle factors are very diﬃcult to evaluate accurately [28],
and one shortcoming in our study is that these factors
were self-reported. We also did not measure sympathetic
nervous activity or endothelial function at the initial visit
or levels of cytokines during the subjects’ subsequent visit.
Future studies should evaluate the possible association
of sympathetic overﬂow and cytokines with respect to
HT.
We conclude that our report provides important evi-
dence regarding the relationship between cytokines and
future BP or HT. This work shows that IL-1β and IL-
1ra are markers for future BP and HT, and thus for
prehypertension, in the normotensive, apparently healthy
population. We suggest that both IL-1β and IL-1ra reﬂect
the same phenomenon, namely, vascular inﬂammation and
arterial stiﬀness. The clinical importance of this study
lies in the fact that both Il-1β and IL-1ra are linked to
increased cardiovascular risk in hypertensive subjects. This
increased risk may reﬂect the presence of extended-duration
proinﬂammatory vasculature stress.
5. SUMMARY
What is known about this topic?
(i) There is evidence that proinﬂammation may be
linked to the development of hypertension.6 Mediators of Inﬂammation
(ii) Increased levels of IL-1β and IL-1ra have been shown
to be linked with essential hypertension in cross-
sectional studies.
What this study adds?
(i) Thislongitudinalstudyofapparentlyhealthymiddle-
aged men and women shows that high levels of
IL-1β and IL-1ra are risk factors for subsequent
hypertension.
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